Julie Richer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Julie Richer has a total of 172 co-authors. Here are the top co-authors by number of shared publications:
Anne-Marie Laberge
Medical Genetics, Department of Pediatrics, CHU Ste-Justine, Montreal, Quebec, Canada
2 shared publications- Bart Loeys
University of Antwerp
2 shared publications Care4Rare Canada Consortium
2 shared publicationsKalin Wilk
Department of Genetics Children's Hospital of Eastern Ontario Ottawa Ontario Canada
2 shared publications- Kristin D. Kernohan
Children's Hospital of Eastern Ontario Research Institute University of Ottawa Ottawa Ontario Canada
2 shared publications - Kym M. Boycott
Department of Genetics Children's Hospital of Eastern Ontario Ottawa Ontario Canada
2 shared publications
Latest Publications
- Open Access
- 5 May 2026
- Published by Wiley in Journal of Genetic Counseling
- Vol. 35 (3) , e70218
Understanding the decision of parents to opt‐out of medically actionable secondary findings offered through genome sequencing
Genomic sequencing (GS) for patients and families with rare disease creates the opportunity for precise diagnosis as well as the option to learn about medically actionable secondary findings (SF). Debate persists internationally on how to manage the analysis and disclosure of SF, especially in settings where service delivery models for GS are still in development and outcomes are preliminary. This study aimed to understand parents' decision to opt‐out of learning about their child's SF for adult‐onset conditions and whether an SF identified in a child was inherited. All children received GS as part of their diagnostic work‐up for a rare disease. Sixteen semistructured interviews were conducted with parents. Guided by a qualitative approach, interviews were analyzed with inductive content analysis. Participants reported that the timing of decision‐making, competing priorities, anticipated adverse psychological outcomes, and health‐related beliefs and worldviews contributed to their decision to opt‐out of receiving SF. An emphasis was placed on a preference for flexible SF delivery models to aid in reducing the burden of SF decision‐making at the time of indication‐based testing. Genetic service delivery models that separate the timing of decisions about indication‐based test results and SF may address patient preferences. Findings from this work may inform clinical practice and policy in jurisdictions where SF delivery models are still being developed and optimized.
- 5 May 2026
- Published by Wiley in Journal of Genetic Counseling
- Vol. 35 (3) , e70218
Open AccessUnderstanding the decision of parents to opt‐out of medically actionable secondary findings offered through genome sequencing
Genomic sequencing (GS) for patients and families with rare disease creates the opportunity for precise diagnosis as well as the option to learn about medically actionable secondary findings (SF). Debate persists internationally on how to manage the analysis and disclosure of SF, especially in settings where service delivery models for GS are still in development and outcomes are preliminary. This study aimed to understand parents' decision to opt‐out of learning about their child's SF for adult‐onset conditions and whether an SF identified in a child was inherited. All children received GS as part of their diagnostic work‐up for a rare disease. Sixteen semistructured interviews were conducted with parents. Guided by a qualitative approach, interviews were analyzed with inductive content analysis. Participants reported that the timing of decision‐making, competing priorities, anticipated adverse psychological outcomes, and health‐related beliefs and worldviews contributed to their decision to opt‐out of receiving SF. An emphasis was placed on a preference for flexible SF delivery models to aid in reducing the burden of SF decision‐making at the time of indication‐based testing. Genetic service delivery models that separate the timing of decisions about indication‐based test results and SF may address patient preferences. Findings from this work may inform clinical practice and policy in jurisdictions where SF delivery models are still being developed and optimized.
- Open Access
- 15 April 2026
- Published by Elsevier in Genetics in Medicine
- Vol. 28 (7) , 102577
Loeys-Dietz syndrome: 2026 updated care management primer
- 15 April 2026
- Published by Elsevier in Genetics in Medicine
- Vol. 28 (7) , 102577
Open AccessLoeys-Dietz syndrome: 2026 updated care management primer
- Open Access
- 4 June 2025
- Published by Wiley in American Journal of Medical Genetics Part A
- p. e64124
Ocular Findings as the Most Striking Manifestation of a SMAD3 Variant
Loeys‐Dietz syndrome (LDS) is a heritable connective tissue disorder with variable expressivity. It is a multisystemic condition mainly characterized by a propensity for arterial aneurysms and dissections, skeletal manifestations, hypertelorism, bifid uvula, craniosynostosis, and cutaneous features. While LDS has significant clinical overlap with other heritable connective tissue disorders such as Marfan syndrome, the ocular manifestations of LDS have not yet been well characterized. We describe an individual with a variant in SMAD3 with a predominantly ocular phenotype and only mild arterial manifestations. The proband presented with early‐onset high myopia (−25 diopters, bilaterally) and bilateral posterior subcapsular cataracts. Ocular phenotype also included esotropia, retinal hemorrhage, glaucoma, bilateral posterior staphylomas, and keratoconjunctivitis sicca. Extensive vascular imaging identified a right internal carotid artery dissection and mild tortuosity of numerous arteries. A molecular gene panel for heritable connective tissue disorders identified a heterozygous SMAD3 c.221G > T; p.(Arg74Leu) variant, initially reported as a variant of uncertain significance and subsequently re‐interpreted as likely pathogenic. Other missense variants at this residue have been reported as pathogenic for LDS. High‐grade myopia, premature cataracts, and premature glaucoma are part of the phenotypic spectrum in LDS caused by SMAD3 variants. Inclusion of SMAD3 in molecular gene panels for early‐onset high‐grade myopia should be considered.
- 4 June 2025
- Published by Wiley in American Journal of Medical Genetics Part A
- p. e64124
Open AccessOcular Findings as the Most Striking Manifestation of a SMAD3 Variant
Loeys‐Dietz syndrome (LDS) is a heritable connective tissue disorder with variable expressivity. It is a multisystemic condition mainly characterized by a propensity for arterial aneurysms and dissections, skeletal manifestations, hypertelorism, bifid uvula, craniosynostosis, and cutaneous features. While LDS has significant clinical overlap with other heritable connective tissue disorders such as Marfan syndrome, the ocular manifestations of LDS have not yet been well characterized. We describe an individual with a variant in SMAD3 with a predominantly ocular phenotype and only mild arterial manifestations. The proband presented with early‐onset high myopia (−25 diopters, bilaterally) and bilateral posterior subcapsular cataracts. Ocular phenotype also included esotropia, retinal hemorrhage, glaucoma, bilateral posterior staphylomas, and keratoconjunctivitis sicca. Extensive vascular imaging identified a right internal carotid artery dissection and mild tortuosity of numerous arteries. A molecular gene panel for heritable connective tissue disorders identified a heterozygous SMAD3 c.221G > T; p.(Arg74Leu) variant, initially reported as a variant of uncertain significance and subsequently re‐interpreted as likely pathogenic. Other missense variants at this residue have been reported as pathogenic for LDS. High‐grade myopia, premature cataracts, and premature glaucoma are part of the phenotypic spectrum in LDS caused by SMAD3 variants. Inclusion of SMAD3 in molecular gene panels for early‐onset high‐grade myopia should be considered.
- 2 January 2025
- Published by BMJ in Journal of Medical Genetics
- Vol. 62 (3) , 199-205
Sexual dimorphism in SMAD3 pathogenic variant-harbouring individuals
Background: Individuals harbouring SMAD3 pathogenic variants are at risk for aneurysms/dissections throughout the arterial tree. Based on prior reports of sex differences in thoracic aortic aneurysm/dissection, we investigated the sexual dimorphism for vascular events in SMAD3-variant-harbouring patients. Methods: We analysed two large pedigrees comprising 84 individuals segregating pathogenic missense variants affecting the same p.Arg287 residue in SMAD3. We excluded individualsSMAD3 patients reported in the literature between 2011 and 2023. Results: In our two pedigrees, 11/30 (37%) variant-harbouring females had no vascular involvement, whereas none of the variant-harboring males (n=23) had no vascular involvement (p=0.001). While the two groups did not differ by age, males were at higher risk of vascular complications (p=0.037), there was no age difference between sexes. Of the 19 females with vascular involvement, six (32%) had vascular involvment sparing the aortic root/ascending aorta, whereas of the 23 males with vascular invovlement, only one (4%) had vascular involvement sparing the aortic root/ascending aorta (p=0.034). In the literature, we identified 116 male and 62 female additional patients. In the combined cohort of 220 patients, we demonstrated an over-representation of males (p<0.001) and non-penetrance in females for vascular pathology involving the aortic root/ascending aorta (p=0.028). Conclusions: Non-penetrance is more common in women, and normal echocardiography in at-risk females is not as reassuring for risk of vasculopathy in other locations. The higher non-penetrance in women creates an ascertainment bias and results in an over-representation of male patients in the literature.
- 2 January 2025
- Published by BMJ in Journal of Medical Genetics
- Vol. 62 (3) , 199-205
Sexual dimorphism in SMAD3 pathogenic variant-harbouring individuals
Background: Individuals harbouring SMAD3 pathogenic variants are at risk for aneurysms/dissections throughout the arterial tree. Based on prior reports of sex differences in thoracic aortic aneurysm/dissection, we investigated the sexual dimorphism for vascular events in SMAD3-variant-harbouring patients. Methods: We analysed two large pedigrees comprising 84 individuals segregating pathogenic missense variants affecting the same p.Arg287 residue in SMAD3. We excluded individualsSMAD3 patients reported in the literature between 2011 and 2023. Results: In our two pedigrees, 11/30 (37%) variant-harbouring females had no vascular involvement, whereas none of the variant-harboring males (n=23) had no vascular involvement (p=0.001). While the two groups did not differ by age, males were at higher risk of vascular complications (p=0.037), there was no age difference between sexes. Of the 19 females with vascular involvement, six (32%) had vascular involvment sparing the aortic root/ascending aorta, whereas of the 23 males with vascular invovlement, only one (4%) had vascular involvement sparing the aortic root/ascending aorta (p=0.034). In the literature, we identified 116 male and 62 female additional patients. In the combined cohort of 220 patients, we demonstrated an over-representation of males (p<0.001) and non-penetrance in females for vascular pathology involving the aortic root/ascending aorta (p=0.028). Conclusions: Non-penetrance is more common in women, and normal echocardiography in at-risk females is not as reassuring for risk of vasculopathy in other locations. The higher non-penetrance in women creates an ascertainment bias and results in an over-representation of male patients in the literature.
- Open Access
- 3 October 2024
- Published by BMJ in Journal of Medical Genetics
- Vol. 61 (12) , 1123-1131
Canadian College of Medical Geneticists: clinical practice advisory document – responsibility to recontact for reinterpretation of clinical genetic testing
Background Advances in technology and knowledge have facilitated both an increase in the number of patient variants reported and variants reclassified. While there is currently no duty to recontact for reclassified genetic variants, there may be a responsibility. The purpose of this clinical practice advisory document is to provide healthcare practitioners guidance for recontact of previously identified and classified variants, suggest methods for recontact, and principles to consider, taking account patient safety, feasibility, ethical considerations, health service capacity and resource constraints. The target audience are practitioners who order genetic testing, follow patients who have undergone genetic testing and those analysing and reporting genetic testing. Methods A multidisciplinary group of laboratory and ordering clinicians, patient representatives, ethics and legal researchers and a genetic counsellor from the Canadian Association of Genetic Counsellors reviewed the existing literature and guidelines on responsibility to recontact in a clinical context to make recommendations. Comments were collected from the Canadian College of Medical Geneticists (CCMG) Education, Ethics, and Public Policy, Clinical Practice and Laboratory Practice committees, and the membership at large. Results Following incorporation of feedback, and external review by the Canadian Association of Genetic Counsellors and patient groups, the document was approved by the CCMG Board of Directors. The CCMG is the Canadian organisation responsible for certifying laboratory and medical geneticists who provide medical genetics services, and for establishing professional and ethical standards for clinical genetics services in Canada. Conclusion The document describes the ethical and practical factors and suggests a shared responsibility between patients, ordering clinician and laboratory practitioners.
- 3 October 2024
- Published by BMJ in Journal of Medical Genetics
- Vol. 61 (12) , 1123-1131
Open AccessCanadian College of Medical Geneticists: clinical practice advisory document – responsibility to recontact for reinterpretation of clinical genetic testing
Background Advances in technology and knowledge have facilitated both an increase in the number of patient variants reported and variants reclassified. While there is currently no duty to recontact for reclassified genetic variants, there may be a responsibility. The purpose of this clinical practice advisory document is to provide healthcare practitioners guidance for recontact of previously identified and classified variants, suggest methods for recontact, and principles to consider, taking account patient safety, feasibility, ethical considerations, health service capacity and resource constraints. The target audience are practitioners who order genetic testing, follow patients who have undergone genetic testing and those analysing and reporting genetic testing. Methods A multidisciplinary group of laboratory and ordering clinicians, patient representatives, ethics and legal researchers and a genetic counsellor from the Canadian Association of Genetic Counsellors reviewed the existing literature and guidelines on responsibility to recontact in a clinical context to make recommendations. Comments were collected from the Canadian College of Medical Geneticists (CCMG) Education, Ethics, and Public Policy, Clinical Practice and Laboratory Practice committees, and the membership at large. Results Following incorporation of feedback, and external review by the Canadian Association of Genetic Counsellors and patient groups, the document was approved by the CCMG Board of Directors. The CCMG is the Canadian organisation responsible for certifying laboratory and medical geneticists who provide medical genetics services, and for establishing professional and ethical standards for clinical genetics services in Canada. Conclusion The document describes the ethical and practical factors and suggests a shared responsibility between patients, ordering clinician and laboratory practitioners.
- 1 May 2024
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 44 (5) , e230087
Imaging Review of Pediatric Monogenic CNS Vasculopathy with Genetic Correlation
Monogenic cerebral vasculopathy is a rare but progressively recognizable cause of pediatric cerebral vasculopathy manifesting as early as fetal life. These monogenic cerebral vasculopathies can be silent or manifest variably as fetal or neonatal distress, neurologic deficit, developmental delay, cerebral palsy, seizures, or stroke. The radiologic findings can be nonspecific, but the presence of disease-specific cerebral and extracerebral imaging features can point to a diagnosis and guide genetic testing, allowing targeted treatment. The authors review the existing literature describing the frequently encountered and rare monogenic cerebral vascular disorders affecting young patients and describe the relevant pathogenesis, with an attempt to categorize them based on the defective step in vascular homeostasis and/or signaling pathways and characteristic cerebrovascular imaging findings. The authors also highlight the role of imaging and a dedicated imaging protocol in identification of distinct cerebral and extracerebral findings crucial in the diagnostic algorithm and selection of genetic testing. Early and precise recognition of these entities allows timely intervention, preventing or delaying complications and thereby improving quality of life. It is also imperative to identify the specific pathogenic variant and pattern of inheritance for satisfactory genetic counseling and care of at-risk family members. Last, the authors present an image-based approach to these young-onset monogenic cerebral vasculopathies that is guided by the size and predominant radiologic characteristics of the affected vessel with reasonable overlap. ©RSNA, 2024 Test Your Knowledge questions for this article are available in the supplemental material.
- 1 May 2024
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 44 (5) , e230087
Imaging Review of Pediatric Monogenic CNS Vasculopathy with Genetic Correlation
Monogenic cerebral vasculopathy is a rare but progressively recognizable cause of pediatric cerebral vasculopathy manifesting as early as fetal life. These monogenic cerebral vasculopathies can be silent or manifest variably as fetal or neonatal distress, neurologic deficit, developmental delay, cerebral palsy, seizures, or stroke. The radiologic findings can be nonspecific, but the presence of disease-specific cerebral and extracerebral imaging features can point to a diagnosis and guide genetic testing, allowing targeted treatment. The authors review the existing literature describing the frequently encountered and rare monogenic cerebral vascular disorders affecting young patients and describe the relevant pathogenesis, with an attempt to categorize them based on the defective step in vascular homeostasis and/or signaling pathways and characteristic cerebrovascular imaging findings. The authors also highlight the role of imaging and a dedicated imaging protocol in identification of distinct cerebral and extracerebral findings crucial in the diagnostic algorithm and selection of genetic testing. Early and precise recognition of these entities allows timely intervention, preventing or delaying complications and thereby improving quality of life. It is also imperative to identify the specific pathogenic variant and pattern of inheritance for satisfactory genetic counseling and care of at-risk family members. Last, the authors present an image-based approach to these young-onset monogenic cerebral vasculopathies that is guided by the size and predominant radiologic characteristics of the affected vessel with reasonable overlap. ©RSNA, 2024 Test Your Knowledge questions for this article are available in the supplemental material.
- Open Access
- 24 July 2023
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 11 (10) , e2247
RNA sequencing resolves novel DYNC2H1 variants causing short‐rib thoracic dysplasia type 3: Case report
Background: Intronic variants outside the canonical splice site are challenging to interpret and therefore likely represent an underreported cause of human disease. Autosomal recessive variants in DYNC2H1 are associated with short‐rib thoracic dysplasia 3 with or without polydactyly (SRTD3), a clinically heterogeneous disease generally presenting with short ribs, shortened tubular bones, narrow thorax and acetabular roof anomalies. We describe a case of SRTD3 with compound heterozygous frameshift and intronic variants and highlight the essential role of RNA sequencing (RNA‐Seq) in variant interpretation.Methods: Following inconclusive clinical genetic testing identifying a likely pathogenic frameshift variant and an intronic variant of uncertain significance (VUS) in DYNC2H1 in trans, the family enrolled in the Care4Rare Canada research program, where RNA‐Seq studies were performed.Results: The proband presented with post‐axial polydactyly of all four limbs, a significantly small chest with a pectus excavatum and anterior flaring of the ribs. RNA‐Seq investigations revealed a novel splice junction as a result of the intronic VUS and significantly decreased DYNC2H1 gene expression in the proband.Conclusion: This case demonstrates the diagnostic utility of RNA‐Seq for variant interpretation following inconclusive clinical testing, which can ultimately lead to diagnosis for patients with rare disease.
- 24 July 2023
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 11 (10) , e2247
Open AccessRNA sequencing resolves novel DYNC2H1 variants causing short‐rib thoracic dysplasia type 3: Case report
Background: Intronic variants outside the canonical splice site are challenging to interpret and therefore likely represent an underreported cause of human disease. Autosomal recessive variants in DYNC2H1 are associated with short‐rib thoracic dysplasia 3 with or without polydactyly (SRTD3), a clinically heterogeneous disease generally presenting with short ribs, shortened tubular bones, narrow thorax and acetabular roof anomalies. We describe a case of SRTD3 with compound heterozygous frameshift and intronic variants and highlight the essential role of RNA sequencing (RNA‐Seq) in variant interpretation.Methods: Following inconclusive clinical genetic testing identifying a likely pathogenic frameshift variant and an intronic variant of uncertain significance (VUS) in DYNC2H1 in trans, the family enrolled in the Care4Rare Canada research program, where RNA‐Seq studies were performed.Results: The proband presented with post‐axial polydactyly of all four limbs, a significantly small chest with a pectus excavatum and anterior flaring of the ribs. RNA‐Seq investigations revealed a novel splice junction as a result of the intronic VUS and significantly decreased DYNC2H1 gene expression in the proband.Conclusion: This case demonstrates the diagnostic utility of RNA‐Seq for variant interpretation following inconclusive clinical testing, which can ultimately lead to diagnosis for patients with rare disease.
- 1 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S265
Utility of incorporating clinical information in variant interpretation for the Fibrillin-1 gene
- 1 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S265
Utility of incorporating clinical information in variant interpretation for the Fibrillin-1 gene
- Open Access
- 26 June 2020
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 43 (6) , 1321-1332
Early infantile epileptic encephalopathy due to biallelic pathogenic variants in PIGQ: Report of seven new subjects and review of the literature
We investigated seven children from six families to expand the phenotypic spectrum associated with an early infantile epileptic encephalopathy caused by biallelic pathogenic variants in the phosphatidylinositol glycan anchor biosynthesis class Q (PIGQ) gene. The affected children were all identified by clinical or research exome sequencing. Clinical data, including EEGs and MRIs, was comprehensively reviewed and flow cytometry and transfection experiments were performed to investigate PIGQ function. Pathogenic biallelic PIGQ variants were associated with increased mortality. Epileptic seizures, axial hypotonia, developmental delay and multiple congenital anomalies were consistently observed. Seizure onset occurred between 2.5 months and 7 months of age and varied from treatable seizures to recurrent episodes of status epilepticus. Gastrointestinal issues were common and severe, two affected individuals had midgut volvulus requiring surgical correction. Cardiac anomalies including arrythmias were observed. Flow cytometry using granulocytes and fibroblasts from affected individuals showed reduced expression of glycosylphosphatidylinositol (GPI)‐anchored proteins. Transfection of wildtype PIGQ cDNA into patient fibroblasts rescued this phenotype. We expand the phenotypic spectrum of PIGQ‐related disease and provide the first functional evidence in human cells of defective GPI‐anchoring due to pathogenic variants in PIGQ.
- 26 June 2020
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 43 (6) , 1321-1332
Open AccessEarly infantile epileptic encephalopathy due to biallelic pathogenic variants in PIGQ: Report of seven new subjects and review of the literature
We investigated seven children from six families to expand the phenotypic spectrum associated with an early infantile epileptic encephalopathy caused by biallelic pathogenic variants in the phosphatidylinositol glycan anchor biosynthesis class Q (PIGQ) gene. The affected children were all identified by clinical or research exome sequencing. Clinical data, including EEGs and MRIs, was comprehensively reviewed and flow cytometry and transfection experiments were performed to investigate PIGQ function. Pathogenic biallelic PIGQ variants were associated with increased mortality. Epileptic seizures, axial hypotonia, developmental delay and multiple congenital anomalies were consistently observed. Seizure onset occurred between 2.5 months and 7 months of age and varied from treatable seizures to recurrent episodes of status epilepticus. Gastrointestinal issues were common and severe, two affected individuals had midgut volvulus requiring surgical correction. Cardiac anomalies including arrythmias were observed. Flow cytometry using granulocytes and fibroblasts from affected individuals showed reduced expression of glycosylphosphatidylinositol (GPI)‐anchored proteins. Transfection of wildtype PIGQ cDNA into patient fibroblasts rescued this phenotype. We expand the phenotypic spectrum of PIGQ‐related disease and provide the first functional evidence in human cells of defective GPI‐anchoring due to pathogenic variants in PIGQ.
- 1 January 2016
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 32 (1) , 60-65
Screening Children for Familial Aortopathies: Tread With Caution
- 1 January 2016
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 32 (1) , 60-65
Screening Children for Familial Aortopathies: Tread With Caution